A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia

M. H. Kirschbaum, T. Synold, A. S. Stein, Joseph Tuscano, J. M. Zain, L. Popplewell, C. Karanes, M. R. O'Donnell, B. Pulone, A. Rincon, J. Wright, P. Frankel, S. J. Forman, E. M. Newman

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1 trial dose-escalation study of tipifarnib on a week-on, week-off schedule in relapsed, refractory or high-risk myeloid leukemia'. Together they form a unique fingerprint.

Medicine & Life Sciences